$PCRX
Pacira Biosciences Inc Stock $pcrx

$pcrx Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000139681422000033 Filed on May 04, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$158.0M	$119.0M
YoY Change	32.74%	12.63%
Cost Of Revenue	$36.07M	$31.35M
YoY Change	15.07%	5.44%
Gross Profit	$121.9M	$87.68M
YoY Change	39.05%	15.44%
Gross Profit Margin	77.17%	73.66%
Selling, General & Admin	$64.26M	$48.52M
YoY Change	32.43%	8.36%
% of Gross Profit	52.71%	55.34%
Research & Development	$21.61M	$15.88M
YoY Change	36.06%	0.38%
% of Gross Profit	17.72%	18.11%
Depreciation & Amortization	$20.03M	$4.851M
YoY Change	312.97%	0.62%
% of Gross Profit	16.43%	5.53%
Operating Expenses	$85.87M	$64.40M
YoY Change	33.33%	6.27%
Operating Profit	$17.39M	$19.44M
YoY Change	-10.52%	13.71%
Interest Expense	$10.25M	$6.971M
YoY Change	46.98%	15.76%
% of Operating Profit	58.91%	35.86%
Other Income/Expense, Net	-$10.10M	-$6.713M
YoY Change	50.44%	-21.37%
Pretax Income	$7.294M	$12.72M
YoY Change	-42.68%	48.7%
Income Tax	$500.0K	$2.400M
% Of Pretax Income	6.85%	18.86%
Net Earnings	$6.828M	$10.37M
YoY Change	-34.15%	27.09%
Net Earnings / Revenue	4.32%	8.71%
Basic Earnings Per Share	$0.15	$0.24
Diluted Earnings Per Share	$0.15	$0.23
COMMON SHARES
Basic Shares Outstanding	44.87M shares	43.83M shares
Diluted Shares Outstanding	46.44M shares	45.97M shares

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$452.2M	$590.1M
YoY Change	-23.37%	85.27%
Cash & Equivalents	$226.8M	$66.70M
Short-Term Investments	$225.4M	$523.4M
Other Short-Term Assets	$19.06M	$13.00M
YoY Change	46.61%	-10.34%
Inventory	$103.7M	$64.61M
Prepaid Expenses
Receivables	$92.10M	$52.58M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$667.0M	$720.2M
YoY Change	-7.39%	66.88%
LONG-TERM ASSETS
Property, Plant & Equipment	$189.8M	$144.8M
YoY Change	31.03%	33.96%
Goodwill	$145.7M	$99.50M
YoY Change	46.43%	0.0%
Intangibles	$609.6M	$94.55M
YoY Change	544.76%	-7.68%
Long-Term Investments	$35.77M	$51.00M
YoY Change	-29.86%	21.14%
Other Assets	$169.3M	$104.5M
YoY Change	61.99%
Total Long-Term Assets	$1.224B	$567.3M
YoY Change	115.84%	45.54%
TOTAL ASSETS
Total Short-Term Assets	$667.0M	$720.2M
Total Long-Term Assets	$1.224B	$567.3M
Total Assets	$1.891B	$1.288B
YoY Change	46.91%	56.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$14.84M	$9.110M
YoY Change	62.93%	-42.52%
Accrued Expenses	$87.67M	$50.24M
YoY Change	74.5%	12.35%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$193.7M	$151.6M
YoY Change	27.76%
Total Short-Term Liabilities	$305.1M	$232.1M
YoY Change	31.45%	188.97%
LONG-TERM LIABILITIES
Long-Term Debt	$729.7M	$317.3M
YoY Change	129.99%	2.32%
Other Long-Term Liabilities	$10.72M	$5.288M
YoY Change	102.76%	244.5%
Total Long-Term Liabilities	$10.72M	$5.288M
YoY Change	102.76%	244.5%
TOTAL LIABILITIES
Total Short-Term Liabilities	$305.1M	$232.1M
Total Long-Term Liabilities	$10.72M	$5.288M
Total Liabilities	$1.182B	$636.7M
YoY Change	85.62%	42.34%
SHAREHOLDERS EQUITY
Retained Earnings	-$157.8M	-$243.5M
YoY Change	-35.18%	-37.76%
Common Stock	$45.00K	$44.00K
YoY Change	2.27%	4.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$709.6M	$650.8M
YoY Change
Total Liabilities & Shareholders Equity	$1.891B	$1.288B
YoY Change	46.91%	56.75%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	$6.828M	$10.37M
YoY Change	-34.15%	27.09%
Depreciation, Depletion And Amortization	$20.03M	$4.851M
YoY Change	312.97%	0.62%
Cash From Operating Activities	$30.78M	$12.08M
YoY Change	154.76%	94.6%
INVESTING ACTIVITIES
Capital Expenditures	$7.668M	$13.07M
YoY Change	-41.34%	94.42%
Acquisitions
YoY Change
Other Investing Activities	-$200.4M	-$42.59M
YoY Change	370.42%	95.01%
Cash From Investing Activities	-$208.0M	-$55.66M
YoY Change	273.7%	94.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$181.6M	$10.33M
YoY Change	-1858.69%	-906.01%
NET CHANGE
Cash From Operating Activities	$30.78M	$12.08M
Cash From Investing Activities	-$208.0M	-$55.66M
Cash From Financing Activities	-$181.6M	$10.33M
Net Change In Cash	-$358.8M	-$33.26M
YoY Change	978.92%	40.69%
FREE CASH FLOW
Cash From Operating Activities	$30.78M	$12.08M
Capital Expenditures	$7.668M	$13.07M
Free Cash Flow	$23.11M	-$992.0K
YoY Change	-2429.54%	92.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001396814
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006RetrospectiveMember
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-35060
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	PACIRA BIOSCIENCES, INC.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	51-0619477
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	5401 West Kennedy Boulevard, Suite 890
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Tampa
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33609
CY2022Q1	dei	City Area Code CityAreaCode	813
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	553-6680
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2022Q1	dei	Trading Symbol TradingSymbol	PCRX
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	45436752	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	226751000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	585578000	USD
CY2022Q1	us-gaap	Short Term Investments ShortTermInvestments	225443000	USD
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	70831000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	92103000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	96318000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	103662000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	98550000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	19059000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14771000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	667018000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	866048000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	189767000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	188401000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	74271000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	76410000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	145722000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	145175000	USD
CY2022Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	609646000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	623968000	USD
CY2022Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	169282000	USD
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	153364000	USD
CY2022Q1	pcrx	Equity Method Investments And Other Assets EquityMethodInvestmentsAndOtherAssets	35770000	USD
CY2021Q4	pcrx	Equity Method Investments And Other Assets EquityMethodInvestmentsAndOtherAssets	21987000	USD
CY2022Q1	us-gaap	Assets Assets	1891476000	USD
CY2021Q4	us-gaap	Assets Assets	2075353000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	14843000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10543000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	87669000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	127555000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8018000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7891000	USD
CY2022Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	160000000	USD
CY2022Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	160000000	USD
CY2021Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	350466000	USD
CY2021Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	350466000	USD
CY2022Q1	us-gaap	Secured Debt Current SecuredDebtCurrent	33680000	USD
CY2021Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	24234000	USD
CY2022Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	863000	USD
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	429000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	305073000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	521118000	USD
CY2022Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	402915000	USD
CY2021Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	339267000	USD
CY2022Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	326828000	USD
CY2021Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	335263000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	69710000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	71727000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	10125000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	10125000	USD
CY2022Q1	pcrx	Contingent Consideration Noncurrent ContingentConsiderationNoncurrent	56527000	USD
CY2021Q4	pcrx	Contingent Consideration Noncurrent ContingentConsiderationNoncurrent	57598000	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	10722000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9847000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	1181900000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	1344945000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	45064459	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	45064459	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44734308	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44734308	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	45000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	45000	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	867890000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	942091000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-157832000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-211895000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-527000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	167000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	709576000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	730408000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1891476000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2075353000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	157991000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	119027000	USD
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	36074000	USD
CY2021Q1	us-gaap	Cost Of Revenue CostOfRevenue	31349000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21605000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15879000	USD
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	64260000	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	48522000	USD
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14322000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1967000	USD
CY2022Q1	pcrx	Acquisition Related Gain Loss Product Discontinuation Costs And Other Net AcquisitionRelatedGainLossProductDiscontinuationCostsAndOtherNet	-4337000	USD
CY2021Q1	pcrx	Acquisition Related Gain Loss Product Discontinuation Costs And Other Net AcquisitionRelatedGainLossProductDiscontinuationCostsAndOtherNet	-1873000	USD
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	140598000	USD
CY2021Q1	us-gaap	Costs And Expenses CostsAndExpenses	99590000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	17393000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	19437000	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	10246000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	6971000	USD
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	271000	USD
CY2021Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	415000	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-124000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-157000	USD
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-10099000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6713000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	7294000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	12724000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	466000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2355000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	6828000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	10369000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.15
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.24
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44869000	shares
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.15
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.23
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43833000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46438000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45966000	shares
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	6828000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	10369000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-733000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-150000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	39000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	4000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-694000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-146000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	6134000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	10223000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	730408000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	11078000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11189000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-694000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	6828000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	709576000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	619688000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	10797000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10110000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-146000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	10369000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	650818000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	6828000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	10369000	USD
CY2022Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	29000	USD
CY2021Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1746000	USD
CY2021Q1	pcrx	Amortization Of Other Assets And Unfavorable Lease Obligation AmortizationOfOtherAssetsAndUnfavorableLeaseObligation	651000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	20033000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4851000	USD
CY2022Q1	pcrx	Amortization Of Other Assets And Unfavorable Lease Obligation AmortizationOfOtherAssetsAndUnfavorableLeaseObligation	1179000	USD
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	706000	USD
CY2021Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	5657000	USD
CY2022Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-9000	USD
CY2021Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	11000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	11189000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	10110000	USD
CY2022Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1071000	USD
CY2021Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1127000	USD
CY2022Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	18000	USD
CY2021Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	155000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4215000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-462000	USD
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5112000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-43000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4260000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-254000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6105000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1351000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-9161000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-18027000	USD
CY2022Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-70000	USD
CY2021Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	1701000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	30777000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	12081000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7668000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13073000	USD
CY2022Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	155601000	USD
CY2021Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	186653000	USD
CY2022Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	0	USD
CY2021Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	145282000	USD
	pcrx	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Accrued Expenses BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenses	547000	USD
CY2022Q1	pcrx	Payment Of Contingent Consideration PaymentOfContingentConsideration	32000000	USD
CY2021Q1	pcrx	Payment Of Contingent Consideration PaymentOfContingentConsideration	0	USD
CY2022Q1	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	12750000	USD
CY2021Q1	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	1220000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-208019000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-55664000	USD
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	11024000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	10325000	USD
CY2022Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	192609000	USD
CY2021Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-181585000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10325000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-358827000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-33258000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	585578000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	99957000	USD
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	9967000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	1686000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	226751000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	66699000	USD
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	9000	USD
CY2021Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1000	USD
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	6244000	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	7033000	USD
CY2022Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
	pcrx	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Liabilities BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilities	547000	USD
	pcrx	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Assets BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssets	0	USD
CY2022Q1	pcrx	Lessee Operating Lease Lease Not Yet Commenced Number Of Contracts LesseeOperatingLeaseLeaseNotYetCommencedNumberOfContracts	1	segment
CY2022Q1	pcrx	Lessee Operating Lease Lease Not Yet Commenced Liability Remainder Of Fiscal Year LesseeOperatingLeaseLeaseNotYetCommencedLiabilityRemainderOfFiscalYear	239000	USD
	pcrx	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Net Assets BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssets	-547000	USD
	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	547000	USD
	us-gaap	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Consideration Transferred BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred	0	USD
CY2022Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	35297000	USD
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	36337000	USD
CY2022Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	33995000	USD
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	35182000	USD
CY2022Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	34370000	USD
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	27031000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	103662000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	98550000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	280488000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	273641000	USD
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	90721000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	85240000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	189767000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	188401000	USD
CY2022Q1	us-gaap	Depreciation Depreciation	5700000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	2900000	USD
CY2022Q1	us-gaap	Asset Retirement Obligation AssetRetirementObligation	3000000	USD
CY2021Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	2400000	USD
CY2022Q1	pcrx	Number Of Leases NumberOfLeases	2	lease
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	3527000	USD
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	2922000	USD
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	472000	USD
CY2021Q1	us-gaap	Variable Lease Cost VariableLeaseCost	478000	USD
CY2022Q1	us-gaap	Lease Cost LeaseCost	3999000	USD
CY2021Q1	us-gaap	Lease Cost LeaseCost	3400000	USD
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	3279000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	4600000	USD
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	16000	USD
CY2021Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y6M18D
CY2021Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y11M12D
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0695
CY2021Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0689
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	9867000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	13304000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	13435000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	12575000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	12310000	USD
CY2022Q1	pcrx	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	39423000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	100914000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	23186000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	77728000	USD
CY2022Q1	pcrx	Lessee Operating Lease Lease Not Yet Commenced Liability Due Year One LesseeOperatingLeaseLeaseNotYetCommencedLiabilityDueYearOne	410000	USD
CY2022Q1	pcrx	Lessee Operating Lease Lease Not Yet Commenced Liability Due Year Two LesseeOperatingLeaseLeaseNotYetCommencedLiabilityDueYearTwo	416000	USD
CY2022Q1	pcrx	Lessee Operating Lease Lease Not Yet Commenced Liability Due Year Three LesseeOperatingLeaseLeaseNotYetCommencedLiabilityDueYearThree	419000	USD
CY2022Q1	pcrx	Lessee Operating Lease Lease Not Yet Commenced Liability Due Year Four LesseeOperatingLeaseLeaseNotYetCommencedLiabilityDueYearFour	425000	USD
CY2022Q1	pcrx	Lessee Operating Lease Lease Not Yet Commenced Liability Due After Year Four LesseeOperatingLeaseLeaseNotYetCommencedLiabilityDueAfterYearFour	179000	USD
CY2022Q1	pcrx	Lessee Operating Lease Lease Not Yet Commenced Liability LesseeOperatingLeaseLeaseNotYetCommencedLiability	2088000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	145700000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	145200000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	590090000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	41444000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	548646000	USD
CY2022Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	651090000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	41444000	USD
CY2022Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	609646000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	590090000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	27122000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	562968000	USD
CY2021Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	651090000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	27122000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	623968000	USD
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14300000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2000000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	43000000	USD
CY2022Q1	pcrx	Finite Lived Intangible Assets Amortization Expense Annual Amount Period12023 Through2029 FiniteLivedIntangibleAssetsAmortizationExpenseAnnualAmountPeriod12023Through2029	57300000	USD
CY2022Q1	pcrx	Finite Lived Intangible Assets Amortization Expense Annual Amount Period2 FiniteLivedIntangibleAssetsAmortizationExpenseAnnualAmountPeriod2	57300000	USD
CY2022Q1	pcrx	Finite Lived Intangible Assets Amortization Expense Annual Amount Period3 FiniteLivedIntangibleAssetsAmortizationExpenseAnnualAmountPeriod3	37400000	USD
CY2022Q1	pcrx	Finite Lived Intangible Assets Amortization Expense Annual Amount Period4 FiniteLivedIntangibleAssetsAmortizationExpenseAnnualAmountPeriod4	7900000	USD
CY2022Q1	pcrx	Finite Lived Intangible Assets Amortization Expense Annual Amount Period5 FiniteLivedIntangibleAssetsAmortizationExpenseAnnualAmountPeriod5	2200000	USD
CY2022Q1	pcrx	Settlement Period Convertible Debt Conversion Request SettlementPeriodConvertibleDebtConversionRequest	P40D
CY2022Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	9130000	USD
CY2021Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	1705000	USD
CY2022Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1179000	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	651000	USD
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	706000	USD
CY2021Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	5657000	USD
CY2022Q1	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	824000	USD
CY2021Q1	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	1042000	USD
CY2022Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	10191000	USD
CY2021Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	6971000	USD
CY2022Q1	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0558
CY2021Q1	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0670
CY2022Q1	us-gaap	Share Price SharePrice	76.32
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	18259000	USD
CY2022Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases	12750000	USD
CY2022Q1	pcrx	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Foreign Currency Gain Loss FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetForeignCurrencyGainLoss	-18000	USD
CY2022Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	30991000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	226413000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	970000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	225443000	USD
CY2022Q1	us-gaap	Interest Receivable InterestReceivable	400000	USD
CY2021Q4	us-gaap	Interest Receivable InterestReceivable	100000	USD
CY2022Q1	pcrx	Number Of Major Customers NumberOfMajorCustomers	3	customer
CY2021	pcrx	Number Of Major Customers NumberOfMajorCustomers	4	segment
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11189000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10110000	USD
CY2022Q1	pcrx	Compensationexpensefromstockoptionsemployees Compensationexpensefromstockoptionsemployees	6785000	USD
CY2021Q1	pcrx	Compensationexpensefromstockoptionsemployees Compensationexpensefromstockoptionsemployees	6496000	USD
CY2022Q1	us-gaap	Restricted Stock Expense RestrictedStockExpense	4113000	USD
CY2021Q1	us-gaap	Restricted Stock Expense RestrictedStockExpense	3392000	USD
CY2022Q1	pcrx	Compensation Expense From Employee Stock Purchase Plan CompensationExpenseFromEmployeeStockPurchasePlan	291000	USD
CY2021Q1	pcrx	Compensation Expense From Employee Stock Purchase Plan CompensationExpenseFromEmployeeStockPurchasePlan	222000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	11189000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	10110000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6050540	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	49.32
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	120200	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	62.24
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	323201	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	34.28
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	33535	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	52.56
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	13054	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	85.48
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5800950	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	50.33
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	27.71
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.85
CY2022Q1	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	0	shares
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	6828000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	10369000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44869000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43833000	shares
CY2022Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2021Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	152000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46438000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45966000	shares
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.15
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.24
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.15
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.23
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9779000	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	892000	shares
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	6582000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	15933000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	712000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-3209000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	7294000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	12724000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	500000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2400000	USD
CY2022Q1	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	3115000	USD
CY2021Q1	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	0	USD
CY2022Q1	pcrx	Business Combination Acquisition And Integration Related Costs BusinessCombinationAcquisitionAndIntegrationRelatedCosts	5408000	USD
CY2021Q1	pcrx	Business Combination Acquisition And Integration Related Costs BusinessCombinationAcquisitionAndIntegrationRelatedCosts	0	USD
CY2022Q1	pcrx	Acquisition Related Charges Product Discontinuation And Other AcquisitionRelatedChargesProductDiscontinuationAndOther	4337000	USD
CY2021Q1	pcrx	Acquisition Related Charges Product Discontinuation And Other AcquisitionRelatedChargesProductDiscontinuationAndOther	1873000	USD

Files In Submission

Name	View Source	Status
0001396814-22-000033-index-headers.html	Edgar Link	pending
0001396814-22-000033-index.html	Edgar Link	pending
0001396814-22-000033.txt	Edgar Link	pending
0001396814-22-000033-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pcrx-20220331.htm	Edgar Link	pending
pcrx-20220331.xsd	Edgar Link	pending
pcrx-20220331_cal.xml	Edgar Link	unprocessable
pcrx-20220331_def.xml	Edgar Link	unprocessable
pcrx-20220331_g1.jpg	Edgar Link	pending
pcrx-20220331_g2.jpg	Edgar Link	pending
pcrx-20220331_htm.xml	Edgar Link	completed
pcrx-20220331_lab.xml	Edgar Link	unprocessable
pcrx-20220331_pre.xml	Edgar Link	unprocessable
pcrx-3312022xex311.htm	Edgar Link	pending
pcrx-3312022xex312.htm	Edgar Link	pending
pcrx-3312022xex321.htm	Edgar Link	pending
q12022exhibit101.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PCRX
Pacira Biosciences Inc Stock $pcrx

2022 Q1 Form 10-Q Financial Statement

#000139681422000033 Filed on May 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCRX Pacira Biosciences Inc Stock $pcrx

2022 Q1 Form 10-Q Financial Statement

#000139681422000033 Filed on May 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCRX
Pacira Biosciences Inc Stock $pcrx